Bionano GenomicsBNGOW 64 Quick Ratio is 1.59 as of Mar. 2026, which is 13% below its 10-year median of 1.82. GuruFocus rates BNGOW with a GF Score™ of 64/100. The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Bionano Genomics ranks worse than 57.61% on this metric.
Bionano Genomics has a quick ratio of 1.59. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bionano Genomics's Quick Ratio or its related term are showing as below:
BNGOW'
s Quick Ratio Range Over the Past 10 Years
Min: 0.33 Med: 1.82 Max: 51.22
Current: 1.59
During the past 10 years, Bionano Genomics's highest Quick Ratio was 51.22. The lowest was 0.33. And the median was 1.82.
BNGOW's Quick Ratio is ranked worse than 57.61% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs BNGOW: 1.59
Bionano Genomics (NAS:BNGOW) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bionano Genomics Quick Ratio Related Terms
Bionano Genomics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bionano Genomics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (BNGOW) has a Quick Ratio of 1.59 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bionano Genomics and its competitors. This is 13% below median its historical median of 1.82. Over the past decade, Bionano Genomics' Quick Ratio has ranged from 0.33 to 51.22. According to the industry distribution chart, Bionano Genomics ranks #492 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 57.6%.
Is Bionano Genomics' Quick Ratio too high?
Bionano Genomics' current Quick Ratio of 1.59 is 13% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 51.22. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Bionano Genomics' value of 1.59 is 14.7% below this industry median. Based on the distribution chart, Bionano Genomics ranks #492 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Quick Ratio compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #492 out of 854 companies for Quick Ratio. This places Bionano Genomics in the lower half of its industry. The industry median Quick Ratio is 1.87. Bionano Genomics' value of 1.59 is 14.7% below this benchmark. Historically, Bionano Genomics' own Quick Ratio has ranged from 0.33 to 51.22 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 1.87, Bionano Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current Quick Ratio of 1.59 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bionano Genomics and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current Quick Ratio is 1.59, which is 13% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Bionano Genomics (BNGOW) has a current Quick Ratio of 1.59. The current Quick Ratio is 1.59, which is 13% below median its 10-year median of 1.82 and 14.7% below the Medical Devices & Instruments industry median of 1.87. Bionano Genomics' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bionano Genomics (BNGOW), the current Quick Ratio is 1.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
64GF Score
Get the complete analysis for BNGOW
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNGOW has been successfully added to your 
